health-it is the sole category represented across all 1 tracked stories. Keith Murphy is most often covered alongside Antibody Drug Conjugates (ADCs), which appears in 1 of these 1 story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention Keith Murphy, all published on June 30, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Keith Murphy
health-it is the sole category represented across all 1 tracked stories. Keith Murphy is most often covered alongside Antibody Drug Conjugates (ADCs), which appears in 1 of these 1 story. Each carries 3 original sources on average. We currently track 1 Healthcare story that mention Keith Murphy, all published on June 30, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 5 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Keith Murphy. Shared-story counts are live from our verified record — not editorial picks.
VivoSim claims its NAMkind platform achieves >90% sensitivity in liver toxicity testing, dramatically reducing false positives that cause expensive drug rejections. This shift aligns with FDA’s drive for human-relevant alternatives to animal testing, promising safer and more efficient drug development.